WHAT IS CLAIMED IS:

1	1.	A method of inducing apoptosis in a cancer cell, the method	
2	comprising contacting the cell with:		
3	i.	an anti-DR4 or anti-DR5 affinity agent agonist; and	
4	ii.	an apoptosis-inducing agent.	
1	2.	The method of claim 1, wherein the agonist is an anti-DR-5 antibody.	
1	3.	The method of claim 2, wherein the anti-DR5 antibody has the binding	
2	specificity of an anti	body comprising a heavy chain variable region comprising the sequence	
3	displayed in Figure 24 or Figure 35 and a light chain variable region as displayed in Figure		
4	25 or Figure 35.		
1	4.	The method of claim 3, wherein the anti-DR5 antibody comprises a	
2	heavy chain variable	region comprising the sequence displayed in Figure 24 or Figure 35 and	
3	a light chain variable region as displayed in Figure 25 or Figure 35.		
1	5.	The method of claim 2, wheren the anti-DR5 antibody is Antibody A	
2	(ATCC Deposit No).		
1	6.	The method of claim 1, wherein the agonist is an anti-DR4 antibody.	
1	7.	The method of claim 1, wherein the cell is contacted with an anti-DR4	
2	antibody agonist and an anti-DR5 antibody agonist.		
1	8.	The method of claim 1, wherein the agonist is a humanized antibody.	
1	9.	The method of claim 1, wherein the agonist is a single chain antibody.	
1	10.	The method of claim 1, wherein the agent prevents or reduces the	
2	expression of BCL-2		
1	11.	The method of claim 10, wherein the agent prevents activation of	
2	NFκB.		
1	12.	The method of claim 11, wherein the agent prevents degradation of	
2	ΙκΒ.		

1 13. The method of claim 1, wherein the agent is a proteasome inhibitor. 14. 1 The method of claim 13, wherein the proteasome inhibitor is selected 2 from the group consisting of PS-341, MG-262 and MG-132. 1 15. The method of claim 1, wherein the agent is an inhibitor of an Inhibitor 2 of Apoptosis (IAP) protein. The method of claim 15, wherein the inhibitor is SMAC or a SMAC 16. 1 2 mimetic. 1 17. The method of claim 1, wherein the cancer cell is a colon cancer cell or 2 a pancreatic cancer cell. The method of claim 1, wherein the agent is an antagonist of PAK1. 1 18. 1 19. The method of claim 1, wherein the agent is an antagonist of a 2 polypeptide selected from the group consisting of nsurf and JIK. 1 20. The method of claim 1, wherein the agent is a siRNA. 1 21. A method of inducing apoptosis in a cancer cell in an individual in 2 need thereof, the method comprising, administering to the individual a therapeutically effective amount of 3 i. an anti-DR4 or anti-DR5 affinity agent agonist; and 4 5 ii. an apoptosis-inducing agent. 1 22. The method of claim 21, wherein the agonist and the agent are 2 administered separately. 1 23. The method of claim 21, wherein the agonist and the agent are 2 administered as a mixture. 1 24. The method of claim 21, wherein the agonist is an anti-DR-5 antibody. The method of claim 24, wherein the anti-DR5 antibody has the 1 25. 2 binding specificity of an antibody comprising a heavy chain variable region comprising the

3 sequence displayed in Figure 24 or Figure 35 and a light chain variable region as displayed in 4 Figure 25 or Figure 35. 26. The method of claim 25, wherein the anti-DR5 antibody comprises a 1 2 heavy chain variable region comprising the sequence displayed in Figure 24 or Figure 35 and 3 a light chain variable region as displayed in Figure 25 or Figure 35. 1 27. The method of claim 25, wherein the anti-DR5 antibody is Antibody A 2 (ATCC Deposit No.). 1 28. The method of claim 21, wherein the agonist is an anti-DR4 antibody. 1 29. The method of claim 21, wherein the cell is contacted with an anti-2 DR4 antibody agonist and an anti-DR5 antibody agonist. 1 30. The method of claim 21, wherein the agonist is a humanized antibody. 1 31. The method of claim 21, wherein the agonist is a single chain antibody. 1 32. The method of claim 21, wherein the agent prevents or reduces the expression of BCL-2 or UbcH10. 2 1 33. The method of claim 32, wherein the agent prevents activation of 2 NFkB. 1 34. The method of claim 33, wherein the agent prevents degradation of 2 ΙκΒ. 1 35. The method of claim 21, wherein the agent is a proteasome inhibitor. 1 36. The method of claim 35, wherein the proteasome inhibitor is selected 2 from the group consisting of PS-341, MG-262 and MG-132. 1 37. The method of claim 21, wherein the agent is an inhibitor of an Inhibitor of Apoptosis (IAP) protein. 2 1 38. The method of claim 37, wherein the inhibitor is SMAC or a SMAC 2 mimetic.

I	39.	The method of claim 21, wherein the cancer cen is a colon cancer cen	
2	or a pancreatic cancer cell.		
1	40.	The method of claim 21, wherein the agent is an antagonist of PAK1.	
1	41.	The method of claim 21, wherein the agent is an antagonist of a	
2	polypeptide selected from the group consisting of UbcH10, nsurf and JIK.		
1	42.	The method of claim 21, wherein the agent is a siRNA.	
1	43. amount of	A physiological composition comprising, a therapeutically effective	
3	i.	an anti-DR4 or anti-DR5 affinity agent agonist; and	
4	ii.	an apoptosis-inducing agent.	
1	44.	The physiological composition of claim 43, wherein the agonist is an	
2	anti-DR-5 antibody.		
1	45.	The physiological composition of claim 44, wherein the anti-DR5	
2		ling specificity of an antibody comprising a heavy chain variable region	
3	comprising the sequence displayed in Figure 24 or Figure 35 and a light chain variable region		
4	as displayed in Figure 25 or Figure 35.		
1	46.	The physiological composition of claim 45, wherein the anti-DR5	
2	antibody comprises a heavy chain variable region comprising the sequence displayed in		
3	Figure 24 or Figure 35 and a light chain variable region as displayed in Figure 25 or Figure		
4	35.		
1	47.	The physiological composition of claim 46, wherein the anti-DR5	
2	antibody is Antibody A (ATCC Deposit No).		
1	48.	The physiological composition of claim 43, wherein the agonist is an	
2	anti-DR4 antibody.		
1	49.	The physiological composition of claim 43, wherein the cell is	
2	contacted with an ant	i-DR4 antibody agonist and an anti-DR5 antibody agonist.	

- 1 50. The physiological composition of claim 43, wherein the agonist is a 2 humanized antibody. The physiological composition of claim 43, wherein the agonist is a 1 51. 2 single chain antibody. 1 52. The physiological composition of claim 43, wherein the agent prevents 2 or reduces the expression of BCL-2 or UbcH10. 1 53. The physiological composition of claim 52, wherein the agent prevents 2 activation of NFkB. 1 54. The physiological composition of claim 53, wherein the agent prevents 2 degradation of IkB. 1 55. The physiological composition of claim 43, wherein the agent is a 2 proteasome inhibitor. 1 56. The physiological composition of claim 43, wherein the agent is an 2 inhibitor of an Inhibitor of Apoptosis (IAP) protein. 1 57. The physiological composition of claim 56, wherein the inhibitor is 2 SMAC or a SMAC mimetic. The physiological composition of claim 43, wherein the agent is an 1 58. 2 antagonist of PAK1. The physiological composition of claim 43, wherein the agent is an 1 59. 2 antagonist of a polypeptide selected from the group consisting of UbcH10, nsurf and JIK.
- 1 60. The physiological composition of claim 43, wherein the agent is a
- 2 siRNA.
- 1 61. An affinity agent with the binding specificity of an antibody 2 comprising a heavy chain variable region comprising the sequence displayed in Figure 24 or 3 Figure 35 and a light chain variable region as displayed in Figure 25 or Figure 35.

- 1 62. The affinity agent of claim 62, which is an antibody comprising a 2 heavy chain variable region comprising the sequence displayed in Figure 24 or Figure 35 and 3 a light chain variable region as displayed in Figure 25 or Figure 35.
 - 63. A cell that expresses the antibody of claim 62.

1

1 64. A method of inducing apoptosis in a cancer cell, the method 2 comprising contacting the cell with an affinity agent with the binding specificity of an 3 antibody comprising a heavy chain variable region comprising the sequence displayed in 4 Figure 24 or Figure 35 and a light chain variable region as displayed in Figure 25 or Figure 5 35.